INSYS Therapeutics Initiates Phase 3 Clinical Trial of Cannabidiol (CBD) Oral Solution for Treatment of Infantile Spasms

PHOENIX, March 02, 2018 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the initiation of a Phase 3 clinical trial to study cannabidiol (CBD) oral solution for the treatment of infantile spasms, a rare type of pediatric epilepsy that occurs in very young children, with the first trial site’s activation.

“We need better treatments for infantile spasms, one of the more severe and dangerous seizure disorders of early childhood,” said Shaun Hussain, M.D., a pediatric neurologist at UCLA Mattel Children’s Hospital and director of its Infantile Spasms Project. “That’s why we’re excited about this pivotal study, which has the potential to reveal a new piece of the treatment puzzle for infantile spasms.”

In previous studies, CBD—one of the main molecules in cannabis—has demonstrated sustained clinical benefits in a

... read more at: https://globenewswire.com/news-release/2018/03/02/1414148/0/en/INSYS-Therapeutics-Initiates-Phase-3-Clinical-Trial-of-Cannabidiol-CBD-Oral-Solution-for-Treatment-of-Infantile-Spasms.html

Leave a Reply

Your email address will not be published. Required fields are marked *